Pegylated Irinotecan NKTR 102 in Treating Patients With Relapsed Small Cell Lung Cancer
Status:
Completed
Trial end date:
2020-02-24
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well pegylated irinotecan NKTR 102 works in treating patients
with small cell lung cancer that has returned after a period of improvement. Pegylated
irinotecan NKTR 102 may stop the growth of tumor cells by blocking some of the enzymes needed
for cell growth.
Phase:
Phase 2
Details
Lead Sponsor:
Roswell Park Cancer Institute
Collaborators:
National Cancer Institute (NCI) Nektar Therapeutics
Treatments:
Camptothecin Irinotecan Topoisomerase I Inhibitors